In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genometrix

Executive Summary

Genometrix has developed a protoype molecular imaging system it believes can demonstrate single molecule detection at a 10-fold throughput advantage over conventional technologies used in sequence-, hybridization-, and amplification-based DNA research and diagnostics protocols.

You may also be interested in...



GE-Genometrix: Dx Imaging Meets Genomics

In an intriguing deal, GE Medical Systems, one of the largest suppliers of MRI and PET equipment, is teaming up with Genometrix, Inc., an applied genomics company in a research collaboration that will combine molecular imaging techniques with genetic probes to develop technologies for detecting and quantifying risk levels for diseases such as breast and prostate cancer.

Aurobindo Upbeat On Outlook, Transfers Biologics Biz

After double-digit growth in formulation sales across geographies in the fourth quarter, Aurobindo expects to continue the momentum this fiscal year. Meanwhile, it might look for partners for its biologics business, which is now transferred to its fully owned subsidiary for $48m.    

Some Annex XVI Products Likely To Be Delayed, Updated European Commission Rolling Plan Suggests

The European Commission has updated its rolling plan. It now looks as if current member state rules for non-medical products could persist beyond the 26 May 2021 deadline.

Topics

UsernamePublicRestriction

Register

LL1132035

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel